BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 32351032)

  • 1. Smad2/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine β-thalassaemia by increasing GATA-1 availability.
    Martinez PA; Li R; Ramanathan HN; Bhasin M; Pearsall RS; Kumar R; Suragani RNVS
    J Cell Mol Med; 2020 Jun; 24(11):6162-6177. PubMed ID: 32351032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.
    Suragani RN; Cawley SM; Li R; Wallner S; Alexander MJ; Mulivor AW; Gardenghi S; Rivella S; Grinberg AV; Pearsall RS; Kumar R
    Blood; 2014 Jun; 123(25):3864-72. PubMed ID: 24795345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luspatercept in the treatment of lower-risk myelodysplastic syndromes.
    Chan O; Komrokji RS
    Future Oncol; 2021 Apr; 17(12):1473-1481. PubMed ID: 33511859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice.
    Tanzi E; Di Modica SM; Bordini J; Olivari V; Pagani A; Furiosi V; Silvestri L; Campanella A; Nai A
    Am J Hematol; 2024 Jul; 99(7):1313-1325. PubMed ID: 38629683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.
    Suragani RN; Cadena SM; Cawley SM; Sako D; Mitchell D; Li R; Davies MV; Alexander MJ; Devine M; Loveday KS; Underwood KW; Grinberg AV; Quisel JD; Chopra R; Pearsall RS; Seehra J; Kumar R
    Nat Med; 2014 Apr; 20(4):408-14. PubMed ID: 24658078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes.
    Verma A; Suragani RN; Aluri S; Shah N; Bhagat TD; Alexander MJ; Komrokji R; Kumar R
    J Clin Invest; 2020 Feb; 130(2):582-589. PubMed ID: 31961337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
    Kang C; Syed YY
    Drugs; 2021 Jun; 81(8):945-952. PubMed ID: 33970460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luspatercept restores SDF-1-mediated hematopoietic support by MDS-derived mesenchymal stromal cells.
    Wobus M; Mies A; Asokan N; Oelschlägel U; Möbus K; Winter S; Cross M; Weidner H; Rauner M; Hofbauer LC; Bornhäuser M; Platzbecker U
    Leukemia; 2021 Oct; 35(10):2936-2947. PubMed ID: 34002031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luspatercept in Myelodysplastic Syndromes: Who and When?
    Komrokji RS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia.
    Dussiot M; Maciel TT; Fricot A; Chartier C; Negre O; Veiga J; Grapton D; Paubelle E; Payen E; Beuzard Y; Leboulch P; Ribeil JA; Arlet JB; Coté F; Courtois G; Ginzburg YZ; Daniel TO; Chopra R; Sung V; Hermine O; Moura IC
    Nat Med; 2014 Apr; 20(4):398-407. PubMed ID: 24658077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia.
    Arlet JB; Ribeil JA; Guillem F; Negre O; Hazoume A; Marcion G; Beuzard Y; Dussiot M; Moura IC; Demarest S; de Beauchêne IC; Belaid-Choucair Z; Sevin M; Maciel TT; Auclair C; Leboulch P; Chretien S; Tchertanov L; Baudin-Creuza V; Seigneuric R; Fontenay M; Garrido C; Hermine O; Courtois G
    Nature; 2014 Oct; 514(7521):242-6. PubMed ID: 25156257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin.
    Carrancio S; Markovics J; Wong P; Leisten J; Castiglioni P; Groza MC; Raymon HK; Heise C; Daniel T; Chopra R; Sung V
    Br J Haematol; 2014 Jun; 165(6):870-82. PubMed ID: 24635723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and GATA-2 upregulation.
    Buck I; Morceau F; Cristofanon S; Heintz C; Chateauvieux S; Reuter S; Dicato M; Diederich M
    Biochem Pharmacol; 2008 Nov; 76(10):1229-39. PubMed ID: 18805401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Luspatercept: First Approval.
    Markham A
    Drugs; 2020 Jan; 80(1):85-90. PubMed ID: 31939073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway.
    De Rosa G; Andolfo I; Marra R; Manna F; Rosato BE; Iolascon A; Russo R
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia.
    Guerra A; Hamilton N; Rivera A; Demsko P; Guo S; Rivella S
    Am J Hematol; 2024 Jul; 99(7):1300-1312. PubMed ID: 38659383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
    Taher AT; Cappellini MD; Kattamis A; Voskaridou E; Perrotta S; Piga AG; Filosa A; Porter JB; Coates TD; Forni GL; Thompson AA; Tartaglione I; Musallam KM; Backstrom JT; Esposito O; Giuseppi AC; Kuo WL; Miteva D; Lord-Bessen J; Yucel A; Zinger T; Shetty JK; Viprakasit V;
    Lancet Haematol; 2022 Oct; 9(10):e733-e744. PubMed ID: 36007538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear interacting SET domain protein 1 inactivation impairs GATA1-regulated erythroid differentiation and causes erythroleukemia.
    Leonards K; Almosailleakh M; Tauchmann S; Bagger FO; Thirant C; Juge S; Bock T; Méreau H; Bezerra MF; Tzankov A; Ivanek R; Losson R; Peters AHFM; Mercher T; Schwaller J
    Nat Commun; 2020 Jun; 11(1):2807. PubMed ID: 32533074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of luspatercept to treat ineffective erythropoiesis.
    Kubasch AS; Fenaux P; Platzbecker U
    Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of miR‑210‑3p on the erythroid differentiation of K562 cells under hypoxia.
    Hu C; Yan Y; Fu C; Ding J; Li T; Wang S; Fang L
    Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34109429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.